v3.25.2
Equity (Tables)
12 Months Ended
Dec. 31, 2024
Equity  
Schedule of common stock outstanding
A.Share capital (in thousands of shares of NIS 5 par value per share)

    

Ordinary shares

2023

    

2024

Issued as of January 1

 

258,564

 

235,597

Repurchase of treasury shares

 

(32,016)

 

(26,043)

Exercise of warrants during the period

 

3,559

 

3

Exercise of share options and RSUs during the period

 

5,490

 

6,220

Issued and paid-in share capital as of December 31

 

235,597

 

215,777

Schedule of stock options activity

Weighted

average

Number

exercise

Weighted average

    

of options

    

price

    

intrinsic value

Outstanding on December 31, 2023

 

4,039,537

$

2.02

$

1.00

Granted

 

 

 

Exercised

 

(856,812)

 

0.74

 

1.70

Forfeited and expired

 

(555,630)

 

2.64

 

1.16

Outstanding on December 31, 2024

 

2,627,095

 

2.30

 

0.80

Exercisable as of December 31, 2024

 

1,421,261

 

2.38

 

0.79

Schedule of valuation assumptions of the options granted

The table below summarizes the assumptions used in determining the fair value of the options granted in 2022-2023:

Range of expected share price volatility

    

103.2%-121.85%

Range of estimated life (years)

 

4.5-8

Range of weighted average of risk-free interest rate

 

4.33%-4.5%

Expected dividend yield

 

Schedule of RSUs activity

Weighted

average

    

Number of Units

    

grant price

Outstanding on December 31, 2023

 

12,468,235

$

3.33

Granted

 

5,817,136

 

2.40

Exercised

 

(4,869,624)

 

3.53

Forfeited

 

(2,522,359)

 

3.32

Outstanding on December 31, 2024

 

10,893,388

$

2.75

Schedule of warrants activity and related information

Weighted

average

Weighted

remaining

average

contractual

exercise

life (in

    

Warrants

    

price

    

years)

Outstanding on December 31, 2023

 

36,465,771

$

6.30

 

1.18

Granted

 

 

  

 

  

Exercised

 

(41,540)

 

2.50

 

0.33

Expired

 

(1,606,605)

 

7.48

 

Outstanding and exercisable as of December 31, 2024

 

34,817,626

$

6.26

 

1.24

Schedule of stock-based compensation expense

For the year ended December 31

    

2022

    

2023

    

2024

Cost of revenues

$

666

 

811

 

938

Research and development expenses

 

12,708

 

10,297

 

6,079

Sales and marketing expenses

 

6,564

 

4,891

 

1,649

General and administrative expenses

 

11,276

 

6,111

 

7,055

$

31,214

 

22,110

 

15,721